Skip to main content

Research News

academics

 

Clinical research courses

  • Molnupiravir has serious safety concern, says ICMR

    Antiviral medicine molnupiravir which recently got approval from the CDSCO in India and is being manufactured by many pharma companies, has serious safety concerns, and thus has not been included in the national COVID-19 clinical protocol recommended by the health ministry, the Indian Council of Medical Research (ICMR) director general Balram Bhargava said.

    Bhargava said the COVID-19 task force has debated twice whether to include the Molnupiravir in the COVID-19 treatment protocol but decided against it because of concerns.

  • New Drug Molnupiravir Get DCGI Approval, Can It Be the Solution for the Fight Against COVID-19

    As countries prepare themselves to fight a possible ‘next wave’. The new variant – Omicron has been making headline and a surge in Covid 19 cases are evident. According to a study based on population-level evidence, the recently identified Omicron variant of SARS-CoV-2 is associated with a substantial ability to evade immunity from prior Covid-19 infection. Omicron is also considered to be three times more transmissible than the Delta variant.

  • Flexibility may be the key to potent peptides for treating diabetes

    New research suggests that the peptides short chunks of protein used to treat Type 2 diabetes may be more effective if they’re able to flexibly move back and forth between different shapes.

  • COVID-19 Can Trigger Self-Attacking Antibodies

    Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery—even among people who had mild symptoms or no symptoms at all, according to Cedars-Sinai investigators. The findings are published in the Journal of Translational Medicine.

  • Novel Drug Delivery, Scientists retool CAR T cells to serve as micropharmacies for Cancer Drugs

    Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patients own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood cancers. Now, scientists at Memorial Sloan Kettering Cancer Centers Sloan Kettering Institute (SKI) have developed new CAR T cells that can do something their predecessors cannot make drugs.

  • Hyrdroxyurea approved by DCGI for Sickle cell anemia

    Sickle cell anemia (SCA) is a common genetic disorder affecting red blood cells in the Indian population. The disease is passed on to children with the faulty beta globin gene from their parents, although the parents themselves do not get the disease. About 0.4% of the population suffers from the disease, while 10% are carriers of the disease, giving rise to new SCA patients.

  • Reservoir of HIV virus in the body

    CD4+ T cells are important parts of the immune system and play a key role in defending the body against pathogens. As they possess a great variety of defense mechanisms against HIV in their resting state, they are infected only very rarely – but these few infected cells form a latent reservoir for HIV in the body that currently cannot be reached by antiviral drugs. Consequently, the virus can spread again from there after activation of the CD4+ T cells.

  • No more annual influenza shot require, suggests new research

    Scientists at Scripps Research, University of Chicago and Icahn School of Medicine at Mount Sinai have identified a new Achilles heel of influenza virus, making progress in the quest for a universal flu vaccine. Antibodies against a long-ignored section of the virus, which the team dubbed the anchor, have the potential to recognize a broad variety of flu strains, even as the virus mutates from year to year, they reported Dec. 23, 2021 in the journal Nature.

  • New Study Adds More Evidence for Omicron Immune Evasion

    A new study from Columbia researchers, in collaboration with scientists at the University of Hong Kong, adds more evidence that the omicron variant can evade the immune protection conferred by vaccines and natural infection and suggests the need for new vaccines and treatments that anticipate how the virus may soon evolve.

  • SARS-CoV-2 goes underground to spread from cell to cell

    The virus that causes COVID-19 has adopted some stealth moves to stay alive and kicking, and one secret to its success is hiding from the immune system by spreading through cell-to-cell transmission, a new study has found. 

    Viruses enter cells to make copies of themselves and cause infection. One secret to SARS-CoV-2’s success is hiding from the immune system by spreading between cells. This transmission electron micrograph shows COVID-causing virus particles that were isolated from a patient.

Subscribe to Research News